Sat. Jul 20th, 2024

The Russian Ministry of Health announced the registration of a drug that has no analogues in the world antibacterial and can be used to treat chronic and stubborn infections.

The drug meets the standards of the Eurasian Economic Union, was named “Phtotiazinon”, and was part of a full production cycle in the Russian Federation.

The ministry statement said that the Gamaleya Center for Epidemiology and Microbiology of the Russian Ministry of Health had fully developed and produced the drug.

The ministry noted that the drug, after tests, showed high safety and therapeutic effectiveness, and is considered a broad-spectrum antibiotic, effective against bacteria resistant to traditional antibiotics.

There are nearly 5 million deaths linked to antibiotic resistance globally each year, and epidemiological research centers are working to find new ways to combat resistant bacterial strains.

Russia and Djibouti cooperate in the field of space exploration

Related Post